OVID

-- -- --

From December 31,2022 to December 31,2023 Issuance of common stock from exercise of stock options and employee stock purchase plan

From June 30, 2023 to September 30, 2023 Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan

From March 31, 2023 to June 30, 2023 Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan

From December 31, 2022 to March 31, 2023 Issuance of common stock from exercise of stock options and purchases from employee stock purchase plan

From June 30, 2022 to September 30, 2022 Issuance of common stock from exercise of stock options and employee stock purchase plan

From March 31, 2022 to June 30, 2022 Issuance of common stock from exercise of stock options

From December 31, 2021 to March 31, 2022 Issuance of common stock from exercise of stock options

From December 31, 2020 to December 31, 2021 Issuance of common stock in asset purchase Issuance of common stock from employee stock purchase plan Issuance of common stock from exercise of stock options Conversion of series A convertible preferred stock to common stock

From June 30, 2021 to September 30, 2021 Issuance of common stock from employee stock purchase plan Issuance of common stock from exercise of stock options

From March 31, 2021 to June 30, 2021 Issuance of common stock from exercise of stock options

From December 31, 2020 To March 31, 2021 Conversion of series A convertible preferred stock to common stock Issuance of common stock from employee stock purchase plan Issuance of common stock from exercise of stock options

From December 31, 2019 to December 31, 2020 Issuance of common stock from employee stock purchase plan Issuance of common stock from exercise of stock options Conversion of series A convertible preferred stock to common stock Proceeds from August 2020 Offering, net of underwriting costs and commissions

From June 30, 2020 to September 30, 2020 Proceeds from August 2020 Offering, net of underwriting costs and commissions Issuance of common stock from employee stock purchase plan Issuance of common stock from exercise of stock options

1.Common stock to be offered by the company 6,250,000 shares. 2.The number of shares of common stock to be outstanding immediately after this offering is based on 57,082,100 shares of common stock outstanding as of June 30, 2020.

From March 31, 2020 to June 30, 2020 Conversion of series A convertible preferred stock to common stock Issuance of common stock from exercise of stock options

From December 31, 2019 to March 31, 2020 Issuance of common stock from employee stock purchase plan

From December 31, 2018 to December 31, 2019 Proceeds from February Offering, net of underwriting costs and commissions Conversion of common stock to series A convertible preferred stock Proceeds from October Offering, net of underwriting costs and commissions Issuance of common stock from employee stock purchase plan Proceeds from ATM transactions, net of underwriting costs and commissions

From June 30, 2019 to September 30, 2019 Conversion of common stock to series A convertible preferred stock Issuance of common stock from ESPP purchase

From December 31, 2018 to March 31, 2019 Proceeds from February Offering, net of underwriting costs and commissions Issuance of common stock from ESPP purchase

Equity Awards:From January 1, 2019 through the date of the filing of this Form 10-K, the Company has granted option awards for an aggregate of 864,963 shares to employees with a weighted average exercise price of $2.18. Public Stock Offering:On February 22, 2019, the Company completed an offering, the February Offering, and sold 12,500,000 shares of its common stock and 2,500 shares of Series A Convertible Preferred Stock at an offering price of $2.00 and $2,000, respectively, for gross proceeds of $30.0 million and $28.2 million of estimated net proceeds after deducting underwriting discounts and commission and other offering expenses. None of these expenses consisted of payments made by us to directors, officers or persons owning 10% or more of our common stock or to their associates, or to our affiliates. Each share of non-voting Series A stock is convertible into 1,000 shares of common stock, provided that conversion will be prohibited, subject to certain exceptions, if, as a result, the holder and its affiliates would beneficially own more than 9.99% of the common stock then outstanding. In addition, the Company has granted the underwriters a 30-day option to purchase an additional 1,750,000 shares of common stock offered in the common stock offering. On February 27, 2019, the underwriters partially exercised a portion of the 30-day option and purchased 1,493,778 shares at an offering price of $2.00 for gross proceeds of $3.0 million and net proceeds of $2.8 million after deducting underwriting discounts and commission and other offering expenses.

From December 31, 2017 to December 31, 2018 Issuance of common stock from exercise of stock options Issuance of common stock from employee stock purchase plan

From December 31, 2016 to December 31, 2017 Proceeds from Initial Public Offering, net of underwriting costs and commissions Conversion of preferred stock into common stock Issuance of common stock from exercise of stock options

From December 31, 2016 to June 30, 2017 Proceeds from Initial Public Offering, net of underwriting costs and commissions Conversion of preferred stock into common stock Issuance of Series B-1 Preferred Stock

1.Common stock to be offered 5,000,000 shares 2.a 1-for-2.15 reverse stock split of our common stock and convertible preferred stock effected on May 1, 2017 3.the automatic conversion of all outstanding shares of our Series A convertible preferred stock and Series B convertible preferred stock as of December 31, 2016 into an aggregate of 7,981,351 shares of our common stock upon the completion of this offering

From December 31, 2016 to March 31, 2017 Issuance of Series B-1 Preferred Stock